Cell BiologyBiology DirectPeer-reviewed
The sensitivity of acute myeloid leukemia to CDK8/19 inhibitors is determined by their metabolic profile
Ekaterina A. Varlamova, Daria V. Andreeva, Alexandra A. Dalina…·Victor Vyacheslavovich Tatarskiy
This study identifies that acute myeloid leukemia (AML) sensitivity to CDK8/19 inhibitors is linked to their metabolic profile, specifically glycolytic activity and TCA disruption.
1 citationtop 4%